Group 1 - YunKang Group (02325.HK) increased by 4.90% [1] - Tongyuan Kang Pharmaceutical-B (02410.HK) rose by 2.73% [1] - Yiming Anke-B (01541.HK) saw a rise of 2.63% [1]

致：香港交易及結算所有限公司 公司名稱: 云康集团有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02325 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 本月底法定/註冊股本總額： USD 50,000 ...

Summary of Key Points Group 1: 52-Week Highs - A total of 45 stocks reached their 52-week highs as of October 23, with notable performers including Base Champion Group (08460) at 234.56%, Tianjin Chuangye Environmental Protection Co., Ltd. (01065) at 136.88%, and Liji Engineering Holdings (01690) at 80.26% [1] - The closing prices and peak prices for the top three stocks are as follows: Base Champion Group closed at 0.250 with a peak of 0.455, Tianjin Chuangye at 4.880 with a peak of 10.020, and Liji Engineering at 0.105 with a peak of 0.137 [1] Group 2: 52-Week Lows - The report also highlighted stocks that reached their 52-week lows, with Huaxi Holdings (01689) showing a decline of 16.67%, China New Economy Equity (02958) down by 14.17%, and Agile Holdings (00186) down by 13.16% [2] - The closing prices and lowest prices for the top three declining stocks are: Huaxi Holdings at 0.400 with a low of 0.350, China New Economy at 0.123 with a low of 0.103, and Agile Holdings at 0.165 with a low of 0.165 [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 云康集团有限公司 | | | | 呈交日期: | 2025年10月6日 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02325 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 USD | | 50,000 | | 增加 / ...

Summary of Key Points Core Viewpoint - As of September 25, a total of 99 stocks reached their 52-week highs, indicating a strong performance in the market, with notable leaders including 精技集团, 辰林教育, and 荣丰集团亚洲, which achieved high rates of increase in their stock prices [1]. Group 1: Stocks Reaching 52-Week Highs - 精技集团 (03302) achieved a closing price of 0.495 with a peak of 0.580, marking a 132.00% increase [1]. - 辰林教育 (01593) closed at 1.490, reaching a high of 3.000, reflecting a 61.29% increase [1]. - 荣丰集团亚洲 (08526) had a closing price of 0.200 and a peak of 0.210, resulting in a 59.09% increase [1]. - 中国集成控股 (01027) reached a closing price of 2.120 with a high of 2.250, showing a 50.00% increase [1]. - 中国光大控股 (00165) closed at 12.790, peaking at 13.240, which is a 26.46% increase [1]. Group 2: Additional Stocks with Significant Increases - K2 F&B (02108) closed at 0.260 with a peak of 0.320, indicating a 25.49% increase [1]. - 中国文旅农业 (00542) reached a closing price of 0.180 and a high of 0.186, marking a 24.00% increase [1]. - 新宇环保 (00436) had a closing price of 0.097 and a peak of 0.098, resulting in a 16.67% increase [1]. - 中国有色矿业 (01258) closed at 13.430 with a peak of 15.680, reflecting a 16.15% increase [1]. - JBB BUILDERS (01903) reached a closing price of 1.420 and a high of 2.020, showing a 16.09% increase [1]. Group 3: Stocks with Lower Increases - 国际精密 (00929) closed at 1.070 with a peak of 1.110, indicating a 15.63% increase [1]. - 极智嘉－Ｗ (02590) had a closing price of 28.680 and a peak of 29.820, resulting in a 13.04% increase [1]. - 德利机械 (02102) closed at 0.246 with a peak of 0.255, marking an 11.84% increase [1]. - 江苏宏信 (02625) reached a closing price of 4.710 and a high of 4.790, reflecting a 10.62% increase [1]. - 博尼控股 (01906) closed at 0.560, remaining stable with a 9.80% increase [1].

Revenue Performance - The company reported revenue of RMB 313.2 million for the six months ended June 30, 2025, a decrease of 17.6% compared to RMB 379.9 million in the same period of 2024[14]. - Revenue from diagnostic outsourcing services was RMB 118.5 million, down 34.0% from RMB 179.6 million in 2024, primarily due to industry policy impacts and intensified market competition[15]. - The revenue from diagnostic testing services provided to medical alliances was RMB 180.3 million, a slight decrease of 1.1% from RMB 182.3 million in 2024[14]. - The group recorded revenue of RMB 180.3 million from diagnostic testing services provided to medical alliances, remaining stable compared to the same period in 2024, and this segment accounted for 57.6% of total revenue, an increase of approximately 9.6% year-on-year[16]. - Revenue from diagnostic testing services for non-medical institutions was RMB 14.4 million, down 20.3% year-on-year, affected by external market conditions and increased competition[41]. - The decline in overall revenue was influenced by factors such as centralized procurement, healthcare cost control, and intensified industry competition[15]. - The group recorded revenue of RMB 313.2 million for diagnostic testing services, a decrease of 17.6% compared to the same period last year[27]. - Revenue for the six months ended June 30, 2025, was RMB 313,217 thousand, a decrease of 17.6% compared to RMB 379,943 thousand for the same period in 2024[128]. Profitability and Losses - The gross profit for the period was RMB 106.4 million, representing a decrease of 17.0% from RMB 128.2 million in the previous year[14]. - The company recorded a loss before tax of RMB 55.4 million, a significant improvement of 58.0% compared to a loss of RMB 131.8 million in 2024[14]. - The loss attributable to owners of the company was RMB 55.3 million, down 56.1% from RMB 126.1 million in the same period last year[14]. - Basic and diluted loss per share was RMB 0.09, a decrease of 57.1% compared to RMB 0.21 in 2024[14]. - The net loss for the group narrowed to RMB 55.4 million, compared to a net loss of RMB 126.1 million in the same period of 2024, primarily due to improved operational and management capabilities, cost control, and reduced financial costs[16]. - The net loss attributable to shareholders for the six months ending June 30, 2025, was RMB 55,340,000, a significant improvement from a net loss of RMB 126,129,000 in the same period of 2024[179]. Cost Management - The cost of revenue was RMB 206.8 million, down 17.8% from RMB 251.7 million in the previous year[14]. - Gross profit decreased by 17.0% to RMB 106.4 million, while the overall gross margin slightly increased from 33.7% to 34.0% due to operational cost optimization[43]. - Sales expenses decreased by 41.0% from RMB 89.9 million for the six months ended June 30, 2024, to RMB 53.1 million for the six months ended June 30, 2025, due to enhanced operational and management capabilities[46]. - Administrative expenses decreased by 21.5% from RMB 99.7 million for the six months ended June 30, 2024, to RMB 78.3 million for the six months ended June 30, 2025, attributed to reduced share-based payment expenses and improved management processes[47]. - Financial asset impairment losses decreased from RMB 52.4 million for the six months ended June 30, 2024, to RMB 8.4 million for the six months ended June 30, 2025, reflecting a reduction in provisions by RMB 44.0 million[48]. - The net financial costs decreased from RMB 24.3 million for the six months ended June 30, 2024, to RMB 15.1 million for the six months ended June 30, 2025, due to optimized debt structure and improved fund management[50]. Strategic Initiatives - The company is actively optimizing its customer structure to provide better services to high-quality clients, which has led to a reduction in revenue in the short term[15]. - The group has provided multi-scenario solutions to nearly 450 medical alliances, enhancing service capabilities and promoting tiered medical service development[28]. - The group aims to cover 50% of tertiary hospitals and 30% of secondary hospitals with intelligent clinical decision support applications by 2027[25]. - The group aims to continue technological innovation and collaboration with industry partners to provide high-cost performance clinical diagnostic solutions[32]. - The implementation of the "one horizontal and one vertical" strategy has strengthened clinical empowerment and operational efficiency[26]. Market Trends and Opportunities - The healthcare industry in China is experiencing high-quality development driven by policy deepening and technological innovation, with a focus on quality, efficiency, and innovation[18]. - The third-party medical testing industry is expected to benefit from the expansion of medical alliances, creating a market space worth hundreds of billions, particularly in emerging fields like molecular diagnostics and genetic testing[20]. - The precision medicine market is in a golden development period, supported by favorable policies and rapid technological advancements, with significant growth potential in the industry[22]. - The development of Laboratory Developed Tests (LDT) is crucial for the clinical transformation of precision medicine, driven by increasing clinical demand for precise diagnostics[23]. Financial Position - Total assets as of June 30, 2025, were RMB 3,060,414 thousand, down from RMB 3,228,336 thousand at the end of 2024[132]. - Total liabilities decreased to RMB 1,957,927 thousand as of June 30, 2025, from RMB 2,078,459 thousand at the end of 2024[132]. - The company’s total equity attributable to shareholders as of June 30, 2025, included a share premium of RMB 610,349,000, unchanged from the previous period[200]. - The company’s total issued ordinary shares remained at 621,250,500 as of June 30, 2025, consistent with the previous year, with no new shares issued during the period[200]. - The company’s cash position showed a decline in bank cash from RMB 1,577,652,000 as of December 31, 2024, to RMB 1,345,889,000 as of June 30, 2025, reflecting a decrease of approximately 14.7%[199]. Employee and Governance - Total employee count decreased to 1,146 as of June 30, 2025, down from 1,459 a year earlier, with total salary costs amounting to RMB 124.6 million for the six months ended June 30, 2025[87]. - The company has adopted a restricted share unit plan to attract and retain key personnel since November 23, 2022[87]. - The company continues to adhere to the corporate governance code and has established a performance evaluation mechanism for restricted share units based on qualitative and quantitative indicators[109]. - The company has confirmed compliance with the standard code for securities trading by all directors during the reporting period[114].

Summary of Key Points Core Viewpoint - As of September 12, 197 stocks reached their 52-week highs, indicating a strong performance in the market, with notable leaders in various sectors [1]. Group 1: Top Performers - The top three stocks that achieved the highest increase in their 52-week high rates are: - Yaojie Ankang-B (02617) with a high rate of 114.69%, closing at 192.500 and reaching a peak of 251.400 [1] - Jinxing Group (00794) with a high rate of 50.00%, closing at 0.210 and peaking at 0.300 [1] - Kaizhile International (02122) with a high rate of 29.51%, closing at 0.360 and peaking at 0.395 [1] Group 2: Additional Notable Stocks - Other notable stocks that reached significant highs include: - Maple Leaf Education (01317) with a 25.00% increase, closing at 0.495 and peaking at 0.550 [1] - Brainstorm Aurora-B (06681) with a 21.25% increase, closing at 7.500 and peaking at 9.470 [1] - Yuhua Education (06169) with a 20.97% increase, closing at 0.730 and peaking at 0.750 [1] Group 3: Market Trends - The overall trend shows a robust market performance with a significant number of stocks hitting new highs, reflecting positive investor sentiment and potential growth opportunities across various sectors [1].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 云康集团有限公司 | | | | 呈交日期: | 2025年9月3日 | | | | I. 法定/註冊股本變動 | | | | 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02325 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 621,250,500 | | 0 | | 621,250,500 | | 增加 / 減少 (-) | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Yunkang Group Limited 云康集团有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2325） 截至本公告日期，董事會成員包括主席兼執行董事張勇先生；非執行董事張為結 先生、王憑慧博士及王瑞華博士；以及獨立非執行董事喻世友先生、謝少華先生 及董敏博士。 更改總部及 中國主要營業地點的地址 云康集团有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司總部及於中 華人民共和國（「中國」）的主要營業地點地址已變更為中國廣東省廣州市黃埔區科 學城荔枝山路6號，自2025年9月1日起生效。 承董事會命 云康集团有限公司 主席 張勇 中國，廣州 2025年9月1日 ...

Core Viewpoint - YunKang Group (02325) reported a revenue of approximately 313 million yuan for the first half of 2025, representing a year-on-year decrease of 17.6%, with a loss attributable to shareholders of 55.34 million yuan, narrowing by 56.1% compared to the previous year [1] Revenue Performance - The decline in revenue is attributed to multiple factors including centralized procurement, healthcare cost control, and intensified industry competition [1] - The diagnostic outsourcing services generated revenue of 118.5 million yuan, a decrease of 34.0% compared to the same period in 2024, due to policy impacts and fierce market competition [1] Loss Reduction Factors - The significant reduction in losses is primarily due to the company's continuous improvement in operational and management capabilities [1] - The gross profit margin has improved compared to the same period last year, while selling and administrative expenses have significantly decreased [1] - The company has actively optimized its debt structure and strengthened cash management, maintaining a net inflow of cash from operating activities, leading to a substantial reduction in financial costs compared to the previous year [1] - The provision for asset impairment losses has decreased compared to the same period last year [1]